Skip to main content
OpenTrials
Completed

NCT Number: NCT02312999

Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery

Study goal: This study will examine whether there is a significant difference in postoperative outcomes between GDFT using a colloid solution versus a crystalloid solution.

Hypothesis: Perioperative fluid optimization through the use of a closed-loop assistance with a balanced starch solution (volulyte®) will be associated with a decrease in postoperative complications compared to the same approach using a balanced crystalloid solution (Plasmalyte®).

Objective: To establish which kind of intravenous fluid used for goal directed therapy with closed-loop assistance will reduce the number of postoperative complications (evaluation made by the POMS score).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

CHU Brugmann, Brussels, Belgium

Loading trial locations.

About this study

Controversy still persists regarding the type of fluid to use in the operating room to avoid hypovolemia and any circulatory insufficiency. While crystalloids and colloid solutions are frequently used to optimize intravascular volume during surgery, crystalloid solutions require more volume for hemodynamic optimization which may result in higher volumes of fluid administration and potentially side effects. Compared with crystalloids, colloids have the advantages of remaining in the intravascular space longer, achieving faster circulatory stabilization, maintaining colloid osmotic pressure and increasing micro perfusion. However, colloids are more expensive and may have various side effects.

In addition to the effect of crystalloids and colloids on the patient, the amount of each fluid administered is also under debate. Goal-directed fluid therapy (GDFT) strategies based on cardiac output (CO) optimization have been shown to benefit moderate- to high-risk surgery patients and have recently been recommended by professional societies in the UK, in France, and in Europe. However, despite the growing evidence, these strategies are often not implemented in current practice. One of the reasons for this lack of implementation is that GDFT strategies, like any other complex clinical protocol, require significant provider attention and vigilance for consistent implementation and it is well known that even under study conditions protocol compliance rates are often not greater than 50% In another hand, one of the chief complicating factors in fluid administration studies is variation in provider administration practices, even when attempting to follow a protocol. Previous studies have used closed-loop (automated) systems to deliver fluid by a standardized protocol, removing variation between providers as one of the confounders of the study. Dr. Cannesson and Rinehart (UC Irvine, California, USA) have recently developed and used a closed-loop system for the provision of GDFT in clinical studies at UC Irvine and La Pitie hospital in France. The closed-loop system is beneficial because it involves the standardization of fluid management and all patients are treated equivalently. This system will thus provide consistent GDFT for all cases in the protocol and remove inter-provider variability as a confounder between groups.

Study goal: This study will examine whether there is a significant difference in postoperative outcomes between GDFT using a colloid solution versus a crystalloid solution.

Hypothesis: Perioperative fluid optimization through the use of a closed-loop assistance with a balanced starch solution (volulyte®) will be associated with a decrease in postoperative complications compared to the same approach using a balanced crystalloid solution (Plasmalyte®).

Objective: To establish which kind of intravenous fluid used for goal directed therapy with closed-loop assistance will reduce the number of postoperative complications (evaluation made by the POMS score).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (over the age of 18) undergoing elective major abdominal surgery that is expected to take longer than 3 hours and requiring a general anesthesia and a minimally invasive cardiac output monitoring (Vigileo/Flotrac)
  • Patients who provide written informed consent

Exclusion criteria

  • Patients under 18 years of age
  • Patients not undergoing surgery, requiring anesthesia, or cardiac output monitoring
  • Patients with arrhythmia and/or atrial fibrillation
  • Patients who are allergic to HES
  • Patients with renal insufficiency (serum creatinine of >2 mg/ml) or hepatic dysfunction (liver enzymes >1.5)
  • Patients who has coagulation disorders (please define: values higher than 1.5x normal values
  • Patients without the capacity to give written informed consent or refusal of consent
  • Patients included in another protocol within a period of 3 months or Participating in another randomised trial
  • Pregnancy at time of enrolment.

Treatment and study plan

PlasmaLyte

Drug

Volulyte

Drug

Primary outcomes

  1. POMS score

    Time frame: 48 hours

    Difference between the 2 groups in postoperative morbidity identified with the Post-Operative Morbidity Survey (POMS score) on postoperative days 2.

Secondary outcomes

  1. Mortality rate

    Time frame: 30 days

    Difference in 30-day post-operative mortality between the 2 groups

  2. Length of hospitalisation

    Time frame: every day up to 90 days after hospitalisation

    Difference in duration of hospital length of stay as well as ICU length of stay.

  3. Quantity of fluid administered during surgery

    Time frame: 24 hours

    Fluid balance during surgery

  4. Transfusion rate

    Time frame: 8 days

    Differences of transfusion rate between the two groups, in ml

  5. Hypotension incidence

    Time frame: 8 days

    Incidence of hypotension (defined as total case time spent with 20% drop from baseline preoperative blood pressure).

  6. Need of vasopressors

    Time frame: 24 hours

    Difference in the need and quantity of vasopressors between the two groups

  7. Mean case cardiac index (L /BSA)

    Time frame: 24 hours

    Mean case cardiac index (L /BSA), Mean case cardiac stroke volume index (mL/ BSA).

  8. Whodas scale

    Time frame: 6 months after surgery

    Enrolled patients will be contacted by phone and their quality of life assessed by the Whodas scale

  9. Whodas scale

    Time frame: 1 year after surgery

    Enrolled patients will be contacted by phone and their quality of life assessed by the Whodas scale

  10. Pruritus apparition

    Time frame: 6 months after surgery

    Enrolled patients will be contacted by phone 6 months after surgery and any pruritus apparition will be recorded

  11. Pruritus apparition

    Time frame: 1 year after surgery

    Enrolled patients will be contacted by phone 1 year after surgery and any pruritus apparition will be recorded

  12. Renal function - urea level

    Time frame: 6 months after surgery

    Urea levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

  13. Renal function - urea level

    Time frame: 1 year after surgery

    Urea levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

  14. Renal function - creatinine level

    Time frame: 6 months after surgery

    Creatinine levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

  15. Renal function - creatinine level

    Time frame: 1 year after surgery

    Creatinine levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

  16. Renal function - Estimated glomerular filtration rate (eGFR)

    Time frame: 6 months after surgery

    Creatinine levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

  17. Renal function - Estimated glomerular filtration rate (eGFR)

    Time frame: 1 year after surgery

    Creatinine levels. Measured in a blood sample taken according to the standard of care outpatient post-operative follow appointments.

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Official study title

Phase IV, Multicentric, Prospective, Controlled, Randomized, Double Blind Study Comparing a Crystalloid to a Colloid Used in the Perioperatory Hemodynamic Optimisation With a 'Closed Loop' Automatic Filling System, on the Post-surgery Morbidity in Major Abdominal Surgery.

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Dec 9, 2014
Registry last updated
Jan 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.